Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials - Castro, M; Zangrilli, J; Wechsler, M E (The Lancet Respiratory medicine, 2015)
. doi:938190 de-38m